TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02827643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement
Description: Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study

Intervention type: OTHER
Group type: OTHER
Intervention: TDF/3TC or FTC/EFV
Description: arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
Study: NCT04526574

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline for injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated influenza vaccine (SIIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated influenza vaccine (SIIV)
Study: NCT04205461

Intervention type: PROCEDURE
Intervention: Programmed ventricular stimulation
Description: Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
Study: NCT03102697

Intervention type: DEVICE
Intervention: Air-filled Intragastric balloon
Description: Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
Study: NCT03848806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1
Description: During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT00000448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
Study: NCT02491125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soluble wheat bran fibre
Description: 12 weeks daily intake of 15g of soluble wheat bran fibre

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks daily intake of 15g of maltodextrin
Study: NCT05158686

Intervention type: DEVICE
Intervention: Paclitaxel-coated Balloon dilation angioplasty
Description: Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization

Intervention type: DEVICE
Intervention: Non-coated Balloon dilation angioplasty
Description: Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
Study: NCT02510313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Description: Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Description: Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.
Study: NCT04289090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane Inhalant Product
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 10 MG/ML
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
Study: NCT03646487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic LP299v 10x10 colony forming units in capsule form
Description: Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in capsule form
Description: Daily placebo in capsule form
Study: NCT01831505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Study: NCT02636556

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
Study: NCT03628248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization of the inferior mesenteric artery
Description: proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior mesenteric artery ligation
Description: Endovascular ligation of Inferior mesenteric artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior mesenteric artery ligation
Description: Endovascular ligation of Inferior mesenteric artery
Study: NCT01416155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Study: NCT01622725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placing the resorbable mesh
Description: Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-resorbable synthetic mesh.
Description: Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
Study: NCT04470284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SMBP
Description: Standard treatment (SMBP-alone)
Study: NCT01683422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton, Gemcitabine, Erlotinib, Capecitabine
Description: Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study: NCT01891318

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: Undergo radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01971632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone & naloxone combination, prolonged release
Study: NCT03575689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doyle Splint
Description: Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
Study: NCT02214823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-Cycling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
Study: NCT02294071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: oral liquid acetaminophen 15mg/kg (max 975mg)
Study: NCT01971632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oxycodone / naloxone
Study: NCT01923337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Given PO
Study: NCT02590757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV-NAVA
Description: Non-invasive neurally adjusted ventilatory assist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-CPAP
Description: Nasal-continuous positive airway pressure
Study: NCT02101333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: intravenous injection 8 mg/kg, monthly during 6 months
Study: NCT01601002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
Study: NCT05691764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
Study: NCT00738166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic or conventional diet
Description: 12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
Study: NCT05691764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo
Study: NCT01279174

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy
Description: Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
Study: NCT00558051

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
Study: NCT01277809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Interaction
Description: Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
Study: NCT02261103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole IR tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Pramipexole ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Pramipexole IR tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard high-fat breakfast
Study: NCT00738166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic or conventional diet
Description: 12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Organic or conventional diet
Description: 12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (organic or conventional)
Description: organic or conventional diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (organic or conventional)
Description: organic or conventional diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet (organic or conventional)
Description: organic or conventional diet
Study: NCT04572568

Intervention type: OTHER
Intervention: Multi-disciplinary assessment
Description: 1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics.
Study: NCT01836848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measuring cerebral perfusion by NIRS with ICG
Description: application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
Study: NCT00203307

Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine during first intervention period and placebo during second intervention period
Description: Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo during first intervention period, then olanzapine during second intervention period
Description: Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
Study: NCT02214823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
Study: NCT00859508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntheCel
Description: Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other FDA cleared dura replacements
Description: Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
Study: NCT03901469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: PO QD
Study: NCT01267058

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' acellular pertussis vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' acellular pertussis vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine
Description: Intramuscular, single dose
Study: NCT03196037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
Study: NCT00650416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets 12.5 mg
Description: 12.5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® Tablets 12.5 mg
Description: 12.5mg, single dose fasting
Study: NCT02427438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: A video with moving demonstration and verbal instruction of the exercise to strengthen low back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
Study: NCT03684824

Intervention type: DRUG
Group type: OTHER
Intervention: Long luteal phase GnRH agonist protocol
Description: Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Gonadotropins
Description: Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
Study: NCT03765424

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultraosund of temporal, carotid and axillary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultraosund of temporal, carotid and axillary arteries
Study: NCT03336723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant
Description: Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant
Description: Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
Study: NCT01267058

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine
Description: Intramuscular, single dose
Study: NCT03672071

Intervention type: OTHER
Group type: OTHER
Intervention: Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)
Description: If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups

Intervention type: OTHER
Group type: OTHER
Intervention: Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)
Description: If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups

Intervention type: OTHER
Group type: OTHER
Intervention: Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)
Description: If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups